Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • Latest news
  • Worldwide impact of NIBSC
  • Mission and values
  • Careers
  • Quality and governance
  • Staff profiles
  • Contact us
  • Collaborations
  • Suppliers
  • Scientific Advisory Committee
  • Minutes of the Animal Welfare and Ethical Review Body
  • Our use of animals
  • Privacy notice
  • Home  /  
  • About us  /  
  • Staff profiles  /  
  • Dr Chris Burns

Dr Chris Burns

Dr Chris Burns joined NIBSC in 2005, initially as a Principal Scientist and then Head of the Endocrinology section. In 2017, he took over as Head of the Division of Biotherapeutics. He has more than 20 years’ research experience obtained initially through doctoral studies and post-doctoral academic research at King’s College London and more recently at NIBSC. He has published more than 50 refereed publications and sits on a number of national and international committees and advisory boards relating to medicine safety, international standardisation and the harmonisation of diagnostic tests. He works closely with the World health Organisation, EDQM, the European and US Pharmacopoeias and the International Federation of Clinical Chemistry and Laboratory Medicine.  

His research interests are focussed in two major areas. The first underpins the activities of the Division of Biotherapeutics at NIBSC and involves the characterisation of biological medicines such as glycoprotein hormones and monoclonal antibodies using physico-chemical and biological assays, and the development of novel and improved methods for these analyses. The second is a program of work using cellular reprogramming to generate induced pluripotent stem cells for studies into the safety of stem cell therapies. These cells have enormous clinical potential for regenerative medicine applications.However, the successful translation of this potential into effective strategies to treat disease relies on a better understanding of the recipient’s immune response to the transplanted cells, and also how these immune responses may be mitigated.

 
Current position

Head, Division of Biotherapeutics

Areas of interest

Endocrinology
Hormones, proteins, peptides
Monoclonal antibodies
International Standardisation
Assay development
Medicine safety
Induced pluripotent stem cells
Embryonic stem cells
Immunogenicity
Humanised mouse models

Qualifications

1998: PhD, Physiology, King’s College London
1995: BSc, Pathobiology, Reading University

Recent publications (PDF, 209KB)

Representation on external committees

  • United States Pharmacopoeia
  • International Federation of Clinical Chemists (IFCC)
  • UK Reference Materials Working Group
  • European Directorate for the Quality of Medicinies (EDQM)
  • Joint Committee for Traceability in Laboratory Medicine
  • British Pharmacopoeia
  • United Kingdom National External Quality Assessment Service (UK NEQAS)
  • Current Stem Cell Research & Therapy, editorial board
External grants and contracts secured over the past 10 years

More than 15 grants and contracts awarded for PhD research studentships, testing of therapeutic products such as Erythropoietin, Somatropin, Follicle-stimulating hormone and Parathyroid hormone and the preparation of compendial reference materials.

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap